FDA Takes New Regulatory Action Against Ranbaxy’s Paonta Sahib Plant in India

[News Reader]

The U.S. Food and Drug Administration today announced that a facility owned by India-based Ranbaxy Laboratories falsified data and test results in approved and pending drug applications. The facility, Paonta Sahib, has been under an FDA Import Alert since September 2008.

More... (http://www.fda.gov/bbs/topics/NEWS/2009/NEW01962.html)